SK14892002A3 - Prípravok majúci mobilizačbú aktivitu - Google Patents
Prípravok majúci mobilizačbú aktivitu Download PDFInfo
- Publication number
- SK14892002A3 SK14892002A3 SK1489-2002A SK14892002A SK14892002A3 SK 14892002 A3 SK14892002 A3 SK 14892002A3 SK 14892002 A SK14892002 A SK 14892002A SK 14892002 A3 SK14892002 A3 SK 14892002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- defibrotide
- csf
- hematopoietic
- capacity
- progenitors
- Prior art date
Links
- 230000003394 haemopoietic effect Effects 0.000 title claims abstract description 51
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 46
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims abstract description 34
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims description 21
- 230000003213 activating effect Effects 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 13
- 239000011886 peripheral blood Substances 0.000 claims abstract description 13
- 230000017531 blood circulation Effects 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 abstract description 4
- 230000004087 circulation Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002960 bfu-e Anatomy 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101100388551 Caenorhabditis elegans glt-3 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salt Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00830293A EP1147777A1 (de) | 2000-04-18 | 2000-04-18 | Kombination von Defibrotid und G-CSF und ihre Verwendung zur Aktivierung der hämatopoiestischen Vorläuferzellen |
| PCT/EP2001/004105 WO2001078761A2 (en) | 2000-04-18 | 2001-04-10 | Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK14892002A3 true SK14892002A3 (sk) | 2003-06-03 |
Family
ID=8175292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1489-2002A SK14892002A3 (sk) | 2000-04-18 | 2001-04-10 | Prípravok majúci mobilizačbú aktivitu |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20040131588A1 (de) |
| EP (3) | EP1147777A1 (de) |
| JP (1) | JP5205668B2 (de) |
| KR (1) | KR100849491B1 (de) |
| CN (1) | CN1183962C (de) |
| AT (2) | ATE310532T1 (de) |
| AU (2) | AU2001258322B2 (de) |
| BG (1) | BG107203A (de) |
| CA (1) | CA2406179C (de) |
| CY (1) | CY1104971T1 (de) |
| CZ (1) | CZ20023426A3 (de) |
| DE (2) | DE60140015D1 (de) |
| DK (2) | DK1276497T3 (de) |
| EE (1) | EE200200596A (de) |
| ES (2) | ES2335776T3 (de) |
| HR (1) | HRP20020835A2 (de) |
| HU (1) | HUP0300560A3 (de) |
| IL (1) | IL152328A (de) |
| IS (1) | IS2171B (de) |
| MX (1) | MXPA02010346A (de) |
| NO (1) | NO20024988L (de) |
| NZ (1) | NZ522016A (de) |
| PL (1) | PL358100A1 (de) |
| PT (1) | PT1621207E (de) |
| RO (1) | RO121006B1 (de) |
| RU (1) | RU2248216C2 (de) |
| SI (1) | SI21079B (de) |
| SK (1) | SK14892002A3 (de) |
| UA (1) | UA73566C2 (de) |
| WO (1) | WO2001078761A2 (de) |
| ZA (1) | ZA200208413B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
| PT1660115E (pt) * | 2003-07-29 | 2011-08-24 | Dompe Spa | ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE |
| WO2005017161A2 (en) | 2003-08-13 | 2005-02-24 | Children's Hospital Medical Center | Chimeric peptides for the regulation of gtpases |
| WO2005017160A2 (en) * | 2003-08-13 | 2005-02-24 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| EP2103689A1 (de) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetische Phosphodiester-Oligonukleotide und deren therapeutische Verwendungen |
| RU2376985C1 (ru) * | 2008-07-17 | 2009-12-27 | Владислав Николаевич Ласкавый | Средство для активации стволовых клеток |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| KR102038357B1 (ko) | 2012-06-22 | 2019-10-31 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (de) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid |
| CN106567694A (zh) * | 2016-11-14 | 2017-04-19 | 北京国泰通源技术有限公司 | 智能控水短节 |
| RU2758487C2 (ru) * | 2018-01-12 | 2021-10-28 | Селлмиг Биолабс Инк. | Способы получения цитокапсул и цитокапсулярных трубок |
| CN114730031B (zh) | 2019-11-13 | 2024-04-12 | 富士胶片株式会社 | 装饰膜、成型物及电子器件 |
| CN117072108B (zh) * | 2023-06-28 | 2026-07-24 | 中国石油天然气集团有限公司 | 一种旋转防喷控压一体化装置、密封方法及控压方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| JP2907447B2 (ja) * | 1988-08-24 | 1999-06-21 | 中外製薬株式会社 | 抗血栓剤 |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| JP3021906B2 (ja) * | 1992-01-28 | 2000-03-15 | 松下電器産業株式会社 | 電動調理機 |
| RU2136667C1 (ru) * | 1995-04-18 | 1999-09-10 | Научно-исследовательский институт фармакологии РАМН | Производные 2-меркаптобензимидазола, обладающие противоишемической, антиаритмической и противофибрилляторной активностью |
| JPH08127539A (ja) * | 1994-10-31 | 1996-05-21 | Ajinomoto Co Inc | ヒトｉｌ−１１を含有する末梢血幹細胞増加剤 |
| US5856444A (en) * | 1994-11-30 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Thrombocytopoiesis stimulating factor |
| ATE299030T1 (de) * | 1996-07-10 | 2005-07-15 | Meiji Dairies Corp | Verwendung von proteinen aus der mk familie als hämatopoietischer faktor |
| WO1999026639A1 (en) * | 1997-11-26 | 1999-06-03 | Allegheny University Of The Health Sciences | Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood |
| US6573372B2 (en) * | 1999-01-07 | 2003-06-03 | Heska Corporation | Feline immunoglobulin E molecules and compositions there of |
-
2000
- 2000-04-18 EP EP00830293A patent/EP1147777A1/de not_active Withdrawn
-
2001
- 2001-04-10 ES ES05108424T patent/ES2335776T3/es not_active Expired - Lifetime
- 2001-04-10 HR HR20020835A patent/HRP20020835A2/xx not_active Application Discontinuation
- 2001-04-10 DE DE60140015T patent/DE60140015D1/de not_active Expired - Lifetime
- 2001-04-10 SI SI200120022A patent/SI21079B/sl not_active IP Right Cessation
- 2001-04-10 RO ROA200201305A patent/RO121006B1/ro unknown
- 2001-04-10 AU AU2001258322A patent/AU2001258322B2/en not_active Ceased
- 2001-04-10 NZ NZ522016A patent/NZ522016A/en unknown
- 2001-04-10 HU HU0300560A patent/HUP0300560A3/hu unknown
- 2001-04-10 PL PL01358100A patent/PL358100A1/xx not_active Application Discontinuation
- 2001-04-10 EP EP01931582A patent/EP1276497B1/de not_active Expired - Lifetime
- 2001-04-10 CA CA2406179A patent/CA2406179C/en not_active Expired - Fee Related
- 2001-04-10 PT PT05108424T patent/PT1621207E/pt unknown
- 2001-04-10 AT AT01931582T patent/ATE310532T1/de active
- 2001-04-10 CZ CZ20023426A patent/CZ20023426A3/cs unknown
- 2001-04-10 JP JP2001576061A patent/JP5205668B2/ja not_active Expired - Fee Related
- 2001-04-10 AU AU5832201A patent/AU5832201A/xx active Pending
- 2001-04-10 ES ES01931582T patent/ES2252227T3/es not_active Expired - Lifetime
- 2001-04-10 KR KR1020027013967A patent/KR100849491B1/ko not_active Expired - Fee Related
- 2001-04-10 US US10/432,741 patent/US20040131588A1/en not_active Abandoned
- 2001-04-10 AT AT05108424T patent/ATE443524T1/de active
- 2001-04-10 WO PCT/EP2001/004105 patent/WO2001078761A2/en not_active Ceased
- 2001-04-10 RU RU2002130719/15A patent/RU2248216C2/ru not_active IP Right Cessation
- 2001-04-10 SK SK1489-2002A patent/SK14892002A3/sk unknown
- 2001-04-10 DK DK01931582T patent/DK1276497T3/da active
- 2001-04-10 MX MXPA02010346A patent/MXPA02010346A/es active IP Right Grant
- 2001-04-10 DE DE60115222T patent/DE60115222T2/de not_active Expired - Lifetime
- 2001-04-10 EE EEP200200596A patent/EE200200596A/xx unknown
- 2001-04-10 IL IL152328A patent/IL152328A/en active IP Right Grant
- 2001-04-10 CN CNB018082025A patent/CN1183962C/zh not_active Expired - Fee Related
- 2001-04-10 EP EP05108424A patent/EP1621207B1/de not_active Expired - Lifetime
- 2001-04-10 DK DK05108424.2T patent/DK1621207T3/da active
- 2001-10-04 UA UA2002119177A patent/UA73566C2/uk unknown
-
2002
- 2002-10-14 IS IS6581A patent/IS2171B/is unknown
- 2002-10-16 NO NO20024988A patent/NO20024988L/no not_active Application Discontinuation
- 2002-10-17 ZA ZA200208413A patent/ZA200208413B/en unknown
- 2002-10-17 BG BG107203A patent/BG107203A/bg unknown
-
2006
- 2006-02-08 CY CY20061100179T patent/CY1104971T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8771663B2 (en) | Formulation having mobilising activity | |
| JP4727988B2 (ja) | エリスロポエチンの使用 | |
| DE60103052T2 (de) | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten | |
| Steward et al. | Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions–a phase I dose-toxicity study | |
| US20070258945A1 (en) | G-GSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction | |
| JP2010235613A (ja) | 内皮前駆細胞の刺激並びに臓器の再生及び内臓障害の進行の抑制のための低用量エリスロポエチンの使用 | |
| KR101192136B1 (ko) | 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제 | |
| EP1276497B1 (de) | Kombination von defibrotid und g-csf und ihre verwendung zur aktivierung hämatopoietischer vorläuferzellen | |
| AU2001258322A1 (en) | Formulation having mobilising activity | |
| JPH11512747A (ja) | 造血幹細胞の動員方法 | |
| KR101144687B1 (ko) | Ｇ－ｃｓｆ 를 함유하는 선유아세포 동원제 및 창상 치료제 | |
| Drapeau et al. | The therapeutic potential of stimulating endogenous stem cell mobilization | |
| DE69829992T2 (de) | Methode zur mobilisierung hematopoietischer stammzellen | |
| HK1212888B (en) | Novel method for treating spinal cord injury using hmgb1 fragment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB9A | Suspension of patent application procedure |